MARKET

ATRA

ATRA

Atara Biotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.55
-0.16
-1.26%
Closed 18:41 08/06 EDT
OPEN
13.20
PREV CLOSE
12.71
HIGH
13.50
LOW
12.20
VOLUME
690.48K
TURNOVER
--
52 WEEK HIGH
19.36
52 WEEK LOW
4.520
MARKET CAP
898.24M
P/E (TTM)
-2.2937
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATRA stock price target is 28.25 with a high estimate of 70.00 and a low estimate of 8.00.

EPS

ATRA News

More
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune
Business Wire · 1d ago
Why Atara Biotherapeutics (ATRA) Might Surprise This Earnings Season
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 2d ago
Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today
Business Wire · 07/29 20:01
IPO Update: AlloVir Proposes Terms For $251 Million IPO
Seeking Alpha · 07/26 16:18
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 07/21 16:00
Will Atara Biotherapeutics Continue to Surge Higher?
Zacks · 07/01 16:28
2 Biotech Stocks That Could Soar in 2020
Motley Fool · 07/01 12:12
Atara Biotherapeutics shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating.
Benzinga · 06/30 15:44

Industry

Biotechnology & Medical Research
-0.96%
Pharmaceuticals & Medical Research
-0.46%

Hot Stocks

Symbol
Price
%Change

About ATRA

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.
More

Webull offers kinds of Atara Biotherapeutics Inc stock information, including NASDAQ:ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.